Gossamer Bio, Inc. (GOSS) vs Spero Therapeutics, Inc. (SPRO)
A side-by-side comparison of Gossamer Bio, Inc. and Spero Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GOSS
Gossamer Bio, Inc.
$10.78HealthcareDelayed quote: Oct 6, 2026, 3:20 PM EDT
SPRO
Spero Therapeutics, Inc.
$1.20HealthcareDelayed quote: Oct 6, 2026, 3:13 PM EDT
Total return — GOSS vs SPRO
growth of $100 · dividends reinvested · last 8yGOSS -99.3% (-45.8%/yr)SPRO -89.4% (-24.5%/yr)SPRO compounded faster over this window
Log scale — wide-divergence pair
GOSS SPRO
GOSS vs SPRO: by the numbers
- •SPRO is the larger company ($69M vs $66M market cap).
- •SPRO is profitable (17.18% net margin) while GOSS runs a net loss (-235.00%).
Metrics side by side
Valuation
| Metric | GOSS | SPRO |
|---|---|---|
| P/E ratio | N/A | 10.90 |
| P/S ratio | 1.24 | 1.62 |
| P/B ratio | N/A | 1.57 |
| EV / EBITDA | N/A | 3.44 |
| FCF yield | N/A | 28.19% |
Profitability
| Metric | GOSS | SPRO |
|---|---|---|
| Gross margin | 99.56% | 100.00% |
| Operating margin | -336.81% | -0.04% |
| Net margin | -235.00% | 17.18% |
| ROE | N/A | 16.70% |
| ROIC | N/A | 13.12% |
Growth (annualized)
| Metric | GOSS | SPRO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 22.93% |
| Total return CAGR (5Y) | -59.51% | -42.70% |
Frequently asked
- Is GOSS or SPRO more profitable?
- SPRO runs the higher net margin — GOSS at -235.00% versus SPRO at 17.18%.
- How have GOSS and SPRO total returns compared?
- Over the past 5 years, GOSS delivered -59.51% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Spero Therapeutics P/E ratioGossamer Bio ROESpero Therapeutics ROEGossamer Bio operating marginSpero Therapeutics operating marginGossamer Bio revenue growthSpero Therapeutics revenue growthGossamer Bio free cash flowSpero Therapeutics free cash flow
Gossamer Bio & Spero Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.